Arbor Biotechnologies’ ABO-101 Gets FDA Orphan Drug, Rare Pediatric Disease Designations
Arbor Biotechnologies received Orphan Drug and Rare Pediatric Disease designations from the U.S. FDA for ABO-101, a gene editing...
Postpartum Incontinence Care Lacking, Survey Reveals
A recent Aeroflow Urology survey of 966 mothers reveals a significant gap in postpartum incontinence care. Despite 85% of...
Study Shows ux111 Gene Therapy Improves Clinical Function in Children with Sanfilippo Syndrome Type A
Ultragenyx Pharmaceutical announced positive data from its pivotal and long-term follow-up studies of UX111 (ABO-102), a gene therapy for...
Annovis’ Buntanetap Enters Phase 3 Alzheimer’s Study
Annovis Bio has initiated its pivotal Phase 3 trial for buntanetap, an oral drug candidate for early-stage Alzheimer’s diseaseAlzheimer’s...
How to Improve Clinical Trials by Empowering the Patient to Share their RWD and Patient-Contributed Data
In the rapidly evolving world of clinical trial technology, Debi Willis, CEO of MyPatientLink, is leading the charge in...
Unbuzzd™ Clinical Trial Success Announced by Quantum Biopharma
Quantum BioPharma Ltd. announced positive results from a clinical trial of its dietary supplement, unbuzzd™, demonstrating its efficacy in...
GlucoTrack Announces Successful Human Clinical Trial of CGM
Glucotrack, Inc. has successfully completed its first human clinical study of a continuous blood glucose monitor (CBGM) implanted in...
10 Bold Solutions to End Cancer: City of Hope’s Plan
City of Hope, a leading cancer research and treatment organization, has outlined strategies to combat rising cancer rates, particularly...
FDA Approves Susvimo for Diabetic Blindness
The FDA approved Susvimo (ranibizumab injection) for diabetic macular edema (DME), a leading cause of vision loss. This marks...
Auron Therapeutics Announces FDA Clearance and Series B Financing
Auron Therapeutics, a clinical-stage biotech company, announced progress on its lead KAT2A/B program and candidate AUTX-703, along with a...